Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus (Q33933474)

30 July 2017

1 reference

title

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus (English)

1 reference

30 July 2017

1 reference

1 reference

1

Gillian M Keating

1 reference

30 July 2017

1 August 2011

1 reference

American journal of cardiovascular drugs

30 July 2017

1 reference

30 July 2017

11

1 reference

30 July 2017

227-247

1 reference

30 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/11207690-000000000-00000

30 July 2017

0 references

cites work

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

European guidelines on cardiovascular disease prevention in clinical practice: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Preventing diabetic complications: a primary care perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Peroxisome proliterator-activated receptors, orphans with ligands and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of fenofibrate and gemfibrozil on plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate inhibits angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of medical therapies on retinopathy progression in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Pharmacoepidemiology safety study of fibrate and statin concomitant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Advances in the medical treatment of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of intensive blood-pressure control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Safety considerations with fibrate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207690-000000000-00000

10.2165/11207690-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

21675801

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

21675801